Bruker PTs Cut to $50 and $49; Teams with Noetik on Tissue Models
Jefferies cut Bruker’s price target from $55 to $50 and BofA lowered its target from $60 to $49, citing a Q4 downturn due to weak U.S. A&G demand and reliance on a strong H2 recovery. Bruker partnered with Noetik to develop tissue models for translational and therapeutic research.
1. Analyst Price Target Cuts
Jefferies reduced its price target on Bruker Corporation from $55 to $50, citing persistent weakness in U.S. A&G demand during Q4. Shortly after, BofA lowered its target from $60 to $49 while maintaining a Buy rating, highlighting the need for a strong H2 2026 rebound to meet full-year expectations.
2. Strategic Collaboration with Noetik
Bruker has entered a collaboration with Noetik to advance tissue foundational models aimed at translational and therapeutic applications. This partnership expands Bruker’s analytical and diagnostic solutions portfolio, potentially opening new revenue streams in life sciences research.
3. Outlook and Implications
Analysts note that 2026 performance hinges on improved A&G demand and margin expansion in the second half. The Noetik deal underscores Bruker’s focus on high-growth research areas, which could support valuation once market conditions stabilize.